KemPharm, Inc. (KMPH) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET

Company Participants

Travis Mickle - Co-Founder, President, CEO & Director

LaDuane Clifton - CFO, Secretary & Treasurer

Conference Call Participants

Jason Rando - Tiberend Strategic Advisors

Operator

Thank you for standing by, and welcome to the KemPharm First Quarter 2022 Results Conference Call. [Operator Instructions].

I would now like to hand the call over to your host, Jason Rando with Tiberend Strategic Advisors. Please go ahead.

Jason Rando

Good afternoon, and thank you for joining our call today to discuss KemPharm's First Quarter 2021 Financial and Corporate Results.

Before we begin, I would like to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties and are subject to change at any time, including but not limited to, statements about KemPharm's expectations regarding future operating results. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations. Actual results may differ materially.

KemPharm disclaims any obligation to update or revise its forward-looking statements, except as required by law. More complete information regarding KemPharm's forward-looking statements, risks and uncertainties can be found in KemPharm's filings with the SEC, which are available on the company's website under the Investor Relations section.

Speaking on today's call will be Travis Mickle, KemPharm's President and CEO; and LaDuane Clifton, CFO. Following remarks, there'll be a question-and-answer session.

With that, it's my pleasure to introduce Travis.

Travis Mickle

Thanks, Jason, and thanks, everyone, for joining today. For those that aren't as familiar with KemPharm, I'll just give a brief introduction here, and discuss our value proposition. KemPharm historically has been focused on the discovery and development of prodrugs. We to date have 2 FDA-approved and partnered medications AZSTARYS and APADAZ and certainly has been the history of the organization. As we announced back in January, our new focus is on rare disease and CNS drug development looking at innovative therapies, including in this particular case, a prodrug, but we're not subject to that limitation. It's this development of these novel treatments, we believe, will create the largest value for us and our shareholders in the future.

Today's update will actually be relatively short. We did provide an update just last -- about 6 weeks ago as well has been making great progress on all of the items that we discussed and had planned for this quarter. There are several items that I have in the update here, that we'll be looking forward to scheduling and/or updating as we move forward.